3 Tertiary Care Hospital Operator, Multi Speciality Hospital Network and Government Partnership Diagnostics Provider Stocks With a Strong Future Roadmap: Global Health, Krishna Institute of Medical Sciences and Krsnaa Diagnostics

Tertiary care and radiology lab stocks offer a focused view of a sector where demand keeps widening. Global Health, Krishna Institute of Medical Sciences and Krsnaa Diagnostics cover a tertiary care hospital operator, a multi speciality hospital network and a government partnership diagnostics provider.

This list covers three tertiary care and radiology lab stocks with complete current figures: Global Health, Krishna Institute of Medical Sciences and Krsnaa Diagnostics. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Tertiary Care and Radiology Lab Stocks?

Tertiary care and radiology lab stocks are listed companies that run large tertiary care hospitals in northern and eastern India, operate multi speciality hospitals with cardiac, neuro and transplant care, and provide radiology and pathology services through government hospital partnerships. Their earnings depend on bed capacity, patient mix and test volumes.

Tertiary Care and Radiology Lab Stocks at a Glance

On valuation, Krsnaa Diagnostics trades at a P/E below the industry P/E, while Global Health and Krishna Institute of Medical Sciences trade above it, which reflects the growth the market already expects. Readers comparing tertiary care and radiology lab stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in tertiary care and radiology lab stocks can use the coming numbers to test whether growth is holding.

Why Do Tertiary Care and Radiology Lab Stocks Have a Strong Roadmap in India?

Tertiary care and radiology lab stocks have a strong roadmap in India because rising incomes, wider health insurance and growing demand for quality care and testing outside the largest cities keep widening the market for these healthcare companies.

• Insurance cover. More families can afford private care.
• Complex care. Cardiac, neuro and transplant services draw steady demand.
• Public partnerships. Government tie ups add test volumes.

Why Global Health Features Among These Tertiary Care and Radiology Lab Stocks

Among the tertiary care and radiology lab stocks on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.

Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.

Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.

Why Krishna Institute of Medical Sciences Features Among These Tertiary Care and Radiology Lab Stocks

Among the bed capacity operator shares on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.

In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%.

Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6.

Roadmap: The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Why Krsnaa Diagnostics Features Among These Tertiary Care and Radiology Lab Stocks

Among the three companies on this list, Krsnaa Diagnostics provides radiology and pathology services through partnerships with government hospitals and through its own diagnostic centres across many states.

The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4.

Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore.

Roadmap: The company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.

What to watch: Track new contract wins, test volumes and the rollout of advanced imaging.

Global Health vs Krishna Institute of Medical Sciences vs Krsnaa Diagnostics on Key Financials

The table below sets the three tertiary care and radiology lab stocks side by side on revenue, profit and margin, using reported figures.

Global Health posts the highest return on equity in this group at 14.1%. Global Health has the largest FY26 revenue at Rs 4,509 crore, and Krishna Institute of Medical Sciences shows the fastest revenue growth with a 23.8% compound annual rate. A useful habit with tertiary care and radiology lab stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several care and testing stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Tertiary Care and Radiology Lab Stocks

Every theme carries risks that deserve a check before any decision. For these tertiary care and radiology lab stocks, the main points are: Long-term bed capacity operator shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Capacity ramp up. New hospitals take time to fill beds and reach full returns.
• Test volumes. Footfall and test mix can vary with seasons.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter tertiary care and radiology lab stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Tertiary Care and Radiology Lab Stocks

Tertiary care and radiology lab stocks reward patient research into demand, execution and financial strength. Global Health, Krishna Institute of Medical Sciences and Krsnaa Diagnostics each have a clear plan to grow. Based on the 28 October 2026 close, Global Health trades at Rs 1,283, Krishna Institute of Medical Sciences at Rs 704.6 and Krsnaa Diagnostics at Rs 496.45. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these tertiary care and radiology lab stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track tertiary care and radiology lab stocks, set price alerts and get research-backed stock ideas.

What are tertiary care and radiology lab stocks?

Ans. Tertiary care and radiology lab stocks are listed companies that run large tertiary care hospitals in northern and eastern India, operate multi speciality hospitals with cardiac, neuro and transplant care, and provide radiology and pathology services through government hospital partnerships. Their earnings depend on bed capacity, patient mix and test volumes. This list looks at three of them, Global Health, Krishna Institute of Medical Sciences and Krsnaa Diagnostics, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.

Which tertiary care and radiology lab stocks are covered in this list?

Ans. This list covers Global Health, Krishna Institute of Medical Sciences and Krsnaa Diagnostics. Based on the 28 October 2026 close, Global Health traded at Rs 1,283, Krishna Institute of Medical Sciences at Rs 704.6 and Krsnaa Diagnostics at Rs 496.45. Their return on equity ranges from 10.3% to 14.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.8% to 23.8%.

Why do tertiary care and radiology lab stocks have a strong future roadmap in India?

Ans. Tertiary care and radiology lab stocks have a strong roadmap in India because rising incomes, wider health insurance and growing demand for quality care and testing outside the largest cities keep widening the market for these healthcare companies. The main drivers are as follows. Insurance cover. More families can afford private care. Complex care. Cardiac, neuro and transplant services draw steady demand. Public partnerships. Government tie ups add test volumes. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Global Health performed financially?

Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

How has Krishna Institute of Medical Sciences performed financially?

Ans. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.

How has Krsnaa Diagnostics performed financially?

Ans. Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4. Looking ahead, the company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.

What risks should investors check before buying tertiary care and radiology lab stocks?

Ans. Investors should check a few risks before buying tertiary care and radiology lab stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Test volumes. Footfall and test mix can vary with seasons. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of tertiary care and radiology lab stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.